Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Oncology Reports

Open Access 23-04-2024 | Breast Cancer | Review

Navigating Breast Cancer Oligometastasis and Oligoprogression: Current Landscape and Future Directions

Authors: Stephanie M. Yoon, Jose G. Bazan

Published in: Current Oncology Reports

Login to get access

Abstract

Purpose

We examine the potential for curative approaches among metastatic breast cancer (MBC) patients by exploring the recent literature on local ablative therapies like surgery and stereotactic body radiation therapy (SBRT) in patients with oligometastatic (OM) breast cancer. We also cover therapies for MBC patients with oligoprogressive (OP) disease.

Key Findings

Surgery and SBRT have been studied for OM and OP breast cancer, mainly in retrospective or non-randomized trials. While many studies demonstrated favorable results, a cooperative study and single-institution trial found no support for surgery/SBRT in OM and OP cases, respectively.

Conclusion

While there is interest in applying local therapies to OM and OP breast cancer, the current randomized data does not back the routine use of surgery or SBRT, particularly when considering the potential for treatment-related toxicities. Future research should refine patient selection through advanced imaging and possibly explore these therapies specifically in patients with hormone receptor-positive or HER2-positive disease.
Literature
1.
2.
3.
Jain DK, Kaushal M, Mathur RK. Epidemiology, acceptability, awareness & management of breast cancer at tertiary centre in India. Breast. 2013;22:S40–0.
4.
Halsted CP, Benson JR, Jatoi I. A historical account of breast cancer surgery: beware of local recurrence but be not radical. Future Oncol. 2014;10(9):1649–57.PubMedCrossRef
5.
Fisher B, Ravdin RG, Ausman RK, Slack NH, Moore GE, Noer RJ. Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation. Ann Surg. 1968;168(3):337.PubMedPubMedCentralCrossRef
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
Hurvitz SA, Dirix L, Kocsis J, et al. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2013;31(9):1157–63.PubMedCrossRef
18.
Albain KS, Nag SM, Calderillo-Ruiz G, et al. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol. 2008;26(24):3950–7.PubMedCrossRef
19.
20.
21.
22.
23.
Cheung P. Stereotactic body radiotherapy for oligoprogressive cancer. The British J Radiol. 2016;89(1066):20160251.CrossRef
24.
Patel PH, Palma D, McDonald F, Tree AC. The dandelion dilemma revisited for oligoprogression: treat the whole lawn or weed selectively? Clin Oncol. 2019;31(12):824–33.CrossRef
25.
26.
27.
28.
Maki DD, Grossman RI. Patterns of disease spread in metastatic breast carcinoma: influence of estrogen and progesterone receptor status. Am J Neuroradiol. 2000;21(6):1064–6.PubMedPubMedCentral
29.
30.
Liu B, Gao S, Li S. A comprehensive comparison of CT, MRI, positron emission tomography or positron emission tomography/CT, and diffusion weighted imaging-MRI for detecting the lymph nodes metastases in patients with cervical cancer: a meta-analysis based on 67 studies. Gynecol Obstetric Invest. 2017;82(3):209–22.CrossRef
31.
32.
33.
Sun Z, Yi YL, Liu Y, Xiong JP, He CZ. Comparison of whole-body PET/PET-CT and conventional imaging procedures for distant metastasis staging in patients with breast cancer: a meta-analysis. Eur J Gynaecol Oncol. 2015;36(6):672–6.PubMed
34.
Hong S, Li J, Wang S. 18FDG PET-CT for diagnosis of distant metastases in breast cancer patients. A meta-analysis. Surg Oncol. 2013;22(2):139–43.PubMedCrossRef
35.
36.
Dashevsky BZ, Goldman DA, Parsons M, et al. Appearance of untreated bone metastases from breast cancer on FDG PET/CT: importance of histologic subtype. Eur J Nuclear Med Mol Imaging. 2015;42:1666–73.CrossRef
37.
Hogan MP, Goldman DA, Dashevsky B, et al. Comparison of 18F-FDG PET/CT for systemic staging of newly diagnosed invasive lobular carcinoma versus invasive ductal carcinoma. J Nuclear Med. 2015;56(11):1674–80.CrossRef
38.
39.
van Kruchten M, de Vries EG, Glaudemans AW, et al. Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer. Cancer Discov. 2015;5(1):72–81.PubMedCrossRef
40.
Evangelista L, Vittoria Dieci M, Guarneri V, Franco CP. 18F-fluoroestradiol positron emission tomography in breast cancer patients: systematic review of the literature & meta-analysis. Curr Radiopharmaceut. 2016;9(3):244–57.CrossRef
41.
Kurland BF, Peterson LM, Lee JH, et al. Estrogen receptor binding (18F-FES PET) and glycolytic activity (18F-FDG PET) predict progression-free survival on endocrine therapy in patients with ER+ breast cancer. Clin Cancer Res. 2017;23(2):407–15.PubMedCrossRef
42.
Wang Y, Ayres KL, Goldman DA, et al. 18F-fluoroestradiol PET/CT measurement of estrogen receptor suppression during a phase I trial of the novel estrogen receptor-targeted therapeutic GDC-0810: using an imaging biomarker to guide drug dosage in subsequent trials. Clin Cancer Res. 2017;23(12):3053–60.PubMedCrossRef
43.
Liu C, Xu X, Yuan H, et al. Dual tracers of 16α-[18F] fluoro-17β-estradiol and [18F] fluorodeoxyglucose for prediction of progression-free survival after fulvestrant therapy in patients with HR+/HER2-metastatic breast cancer. Front Oncol. 2020;10:580277.PubMedPubMedCentralCrossRef
44.
He M, Liu C, Shi Q, et al. The predictive value of early changes in 18F-fluoroestradiol positron emission tomography/computed tomography during fulvestrant 500 mg therapy in patients with estrogen receptor-positive metastatic breast cancer. The Oncologist. 2020;25(11):927–36.PubMedPubMedCentralCrossRef
45.
Mo JA. Safety and effectiveness of F-18 fluoroestradiol positron emission tomography/computed tomography: a systematic review and meta-analysis. J Korean Med Sci. 2021;36(42)
46.
Van Geel JJ, Boers J, Elias SG, et al. Clinical validity of 16α-[18F] fluoro-17β-estradiol positron emission tomography/computed tomography to assess estrogen receptor status in newly diagnosed metastatic breast cancer. J Clin Oncol. 2022;40(31):3642–52.PubMedCrossRef
47.
Boers J, Loudini N, de Haas RJ, et al. Analyzing the estrogen receptor status of liver metastases with [18F]-FES-PET in patients with breast cancer. Diagnostics. 2021;11(11):2019.PubMedPubMedCentralCrossRef
48.
49.
50.
Gerlinger M. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing (vol 366, pg 883, 2012). New England J Med. 2012;367(10):976–6.CrossRef
51.
Pasha N, Turner NC. Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatment. Nat Cancer. 2021;2(7):680–92.PubMedCrossRef
52.
Brown D, Smeets D, Székely B, et al. Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations. Nat Commun. 2017;8(1):14944.PubMedPubMedCentralCrossRef
53.
Bertucci F, Ng CK, Patsouris A, et al. Genomic characterization of metastatic breast cancers. Nature. 2019;569(7757):560–4.PubMedCrossRef
54.
55.
De Mattos-Arruda L, Sammut SJ, Ross EM, et al. The genomic and immune landscapes of lethal metastatic breast cancer. Cell Rep. 2019;27(9):2690–2708. e10.PubMedPubMedCentralCrossRef
56.
Cejalvo JM, Martínez de Dueñas E, Galván P, et al. Intrinsic subtypes and gene expression profiles in primary and metastatic breast cancer. Cancer Res. 2017;77(9):2213–21.PubMedPubMedCentralCrossRef
57.
Gennari A, André F, Barrios CH, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer☆. Ann Oncol. 2021;32(12):1475–95.PubMedCrossRef
58.
Guarneri V, Giovannelli S, Ficarra G, et al. Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management. The Oncologist. 2008;13(8):838–44.PubMedCrossRef
59.
Dieci MV, Barbieri E, Piacentini F, et al. Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysis. Ann Oncol. 2013;24(1):101–8.PubMedCrossRef
60.
Grinda T, Joyon N, Lusque A, et al. Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort. NPJ Breast Cancer. 2021;7(1):41.PubMedPubMedCentralCrossRef
61.
62.
63.
64.
65.
Planchard D, Popat ST, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv192-iv237.PubMedCrossRef
66.
67.
Palma DA, Louie AV, Rodrigues GB. New strategies in stereotactic radiotherapy for oligometastases. Clin Cancer Res. 2015;21(23):5198–204.PubMedCrossRef
68.
McDonald ML, Deschamps C, Ilstrup DM, Allen MS, Trantek VF, Pairolero PC. Pulmonary resection for metastatic breast cancer. The Ann Thoracic surg. 1994;58(6):1599–602.CrossRef
69.
70.
Yhim HY, Han SW, Oh DY, et al. Prognostic factors for recurrent breast cancer patients with an isolated, limited number of lung metastases and implications for pulmonary metastasectomy. Cancer. 2010;116(12):2890–901.PubMedCrossRef
71.
Vlastos G, Smith DL, Singletary SE, et al. Long-term survival after an aggressive surgical approach in patients with breast cancer hepatic metastases. Ann Surg Oncol. 2004;11:869–74.PubMedCrossRef
72.
Abbott DE, Brouquet A, Mittendorf EA, et al. Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome. Surgery. 2012;151(5):710–6.PubMedCrossRef
73.
Fan J, Chen D, Du H, Shen C, Che G. Prognostic factors for resection of isolated pulmonary metastases in breast cancer patients: a systematic review and meta-analysis. J Thoracic Dis. 2015;7(8):1441.
74.
75.
76.
77.
78.
79.
80.
Yan Y, Tang L, Tong W, Zhou J. The role and indications of aggressive locoregional therapy in metastatic inflammatory breast cancer. Sci Rep. 2016;6(1):25874.PubMedPubMedCentralCrossRef
81.
Akay CL, Ueno NT, Chisholm GB, et al. Primary tumor resection as a component of multimodality treatment may improve local control and survival in patients with stage IV inflammatory breast cancer. Cancer. 2014;120(9):1319–28.PubMedCrossRef
82.
van Uden DJP, van Maaren MC, Strobbe LJA, et al. Better survival after surgery of the primary tumor in stage IV inflammatory breast cancer. Surg Oncol. 2020;33:43–50.PubMedCrossRef
83.
Partain N, Postlewait LM, Teshome M, et al. The role of mastectomy in de novo stage IV inflammatory breast cancer. Ann Surg Oncol. 2021;28:4265–74.PubMedCrossRef
84.
Weiss A, Menen RS, Lin HY, et al. Factors associated with improved outcomes for metastatic inflammatory breast cancer patients. Breast Cancer Res Treat. 2018;169:615–23.PubMedCrossRef
85.
Chen JC, Li Y, Fisher JL, et al. Modified radical mastectomy in de novo stage IV inflammatory breast cancer. Ann Surg Oncol. 2022;29(11):6681–8.PubMedCrossRef
86.
Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. New England J Med. 1990;322(8):494–500.CrossRef
87.
Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. Jama. 1998;280(17):1485–9.PubMedCrossRef
88.
Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. Jama. 2006;295(21):2483–91.PubMedCrossRef
89.
Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. The Lancet Oncol. 2009;10(11):1037–44.PubMedCrossRef
90.
Murthy RK, Loi S, Okines A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. New England J Med. 2019;382(7):597–609.CrossRef
91.
Bartsch R, Berghoff AS, Furtner J, et al. Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial. Nat Med. 2022;28(9):1840–7.PubMedPubMedCentralCrossRef
92.
93.
94.
Phillips R, Lim SJ, Shi WY, et al. Primary outcomes of a phase II randomized trial of observation versus stereotactic ablative radiation for oligometastatic prostate cancer (ORIOLE). Int J Radiat Oncol Biol Phys. 2019;105(3):681.CrossRef
95.
96.
97.
98.
99.
100.
Scorsetti M, Franceschini D, De Rose F, et al. Stereotactic body radiation therapy: a promising chance for oligometastatic breast cancer. The Breast. 2016;26:11–7.PubMedCrossRef
101.
Onal C, Guler OC, Yildirim BA. Treatment outcomes of breast cancer liver metastasis treated with stereotactic body radiotherapy. The Breast. 2018;42:150–6.PubMedCrossRef
102.
103.
104.
Tan H, Cheung P, Louie AV, et al. Outcomes of extra-cranial stereotactic body radiotherapy for metastatic breast cancer: treatment indication matters. Radiother Oncol. 2021;161:159–65.PubMedCrossRef
105.
106.
Milano MT, Katz AW, Zhang H, Huggins CF, Aujla KS, Okunieff P. Oligometastatic breast cancer treated with hypofractionated stereotactic radiotherapy: some patients survive longer than a decade. Radiother Oncol. 2019;131:45–51.PubMedCrossRef
107.
108.
109.
110.
Im SA, Lu YS, Bardia A, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. New England J Med. 2019;381(4):307–16.CrossRef
111.
Turner NC, Slamon DJ, Ro J, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. New England J Med. 2018;379(20):1926–36.CrossRef
112.
Sledge GW Jr, Toi M, Neven P, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2− advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875–84.PubMedCrossRef
113.
Slamon DJ, Neven P, Chia S, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. New England J Med. 2019;382(6):514–24.CrossRef
114.
Cortes J, Rugo HS, Cescon DW, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. New England J Med. 2022;387(3):217–26.CrossRef
115.
Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. New England J Med. 2015;372(8):724–34.CrossRef
116.
Iyengar P, Kavanagh BD, Wardak Z, et al. Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non–small-cell lung cancer. J Clin Oncol. 2014;32(34):3824–30.PubMedCrossRef
117.
Weiss J, Kavanagh B, Deal A, et al. Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib. Cancer Treat Res Commun. 2019;19:100126.PubMedCrossRef
118.
Phillips R, Shi WY, Deek M, et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol. 2020;6(5):650–9.PubMedPubMedCentralCrossRef
119.
Berghen C, Joniau S, Rans K, et al. Metastasis-directed therapy for oligoprogressive castration-resistant prostate cancer―preliminary results of the prospective, single-arm MEDCARE trial. Int J Radiat Oncol Biol Phys. 2021;111(3):e265–6.CrossRef
120.
121.
Pasalic D, McGinnis GJ, Fuller CD, et al. Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials. Eur J Cancer. 2020;136:176–85.PubMedPubMedCentralCrossRef
122.
Tsai CJ, Yang JT, Shaverdian N, et al. Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (consolidative use of radiotherapy to block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study. The Lancet., 403. 2023;(10422):171–82.
123.
124.
Katzenellenbogen JA. PET imaging agents (FES, FFNP, and FDHT) for estrogen, androgen, and progesterone receptors to improve management of breast and prostate cancers by functional imaging. Cancers. 2020;12(8):2020.PubMedPubMedCentralCrossRef
125.
Ulaner GA, Hyman DM, Ross DS, et al. Detection of HER2-positive metastases in patients with HER2-negative primary breast cancer using 89Zr-trastuzumab PET/CT. J Nuclear Med. 2016;57(10):1523–8.CrossRef
126.
Dehdashti F, Wu N, Ma CX, Naughton MJ, Katzenellenbogen JA, Siegel BA. Association of PET-based estradiol-challenge test for breast cancer progesterone receptors with response to endocrine therapy. Nat Commun. 2021;12(1):733.PubMedPubMedCentralCrossRef
127.
Lebron L, Greenspan D, Pandit-Taskar N. PET imaging of breast cancer: role in patient management. PET Clinics. 2015;10(2):159–95.PubMedCrossRef
128.
Mortimer JE, Bading JR, Park JM, et al. Tumor uptake of 64Cu-DOTA-trastuzumab in patients with metastatic breast cancer. J Nuclear Med. 2018;59(1):38–43.CrossRef
129.
Venema CM, Mammatas LH, Schröder CP, et al. Androgen and estrogen receptor imaging in metastatic breast cancer patients as a surrogate for tissue biopsies. J Nuclear Med. 2017;58(12):1906–12.CrossRef
130.
Jacene H, Liu M, Cheng SC, et al. Imaging androgen receptors in breast cancer with 18F-fluoro-5α-dihydrotestosterone PET: a pilot study. J Nuclear Med. 2022;63(1):22–8.CrossRef
131.
Loktev A, Lindner T, Mier W, et al. A tumor-imaging method targeting cancer-associated fibroblasts. J Nuclear Med. 2018;59(9):1423–9.CrossRef
132.
Kratochwil C, Flechsig P, Lindner T, et al. 68Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer. J Nuclear Med. 2019;60(6):801–5.CrossRef
133.
Hicks RJ, Roselt PJ, Kallur KG, Tothill RW, Mileshkin L. FAPI PET/CT: will it end the hegemony of 18F-FDG in oncology? J Nuclear Med. 2021;62(3):296–302.CrossRef
134.
Kömek H, Can C, Güzel Y, et al. 68 Ga-FAPI-04 PET/CT, a new step in breast cancer imaging: a comparative pilot study with the 18 F-FDG PET/CT. Ann Nuclear Med. 2021;35:744–52.CrossRef
135.
136.
137.
Lussier YA, Khodarev NN, Regan K, et al. Oligo-and polymetastatic progression in lung metastasis (es) patients is associated with specific microRNAs. PloS one. 2012;7(12):e50141.PubMedPubMedCentralCrossRef
138.
139.
Valastyan S, Weinberg RA. MicroRNAs: crucial multi-tasking components in the complex circuitry of tumor metastasis. Cell Cycle. 2009;8(21):3506–12.PubMedCrossRef
140.
Dhaka S, Tripathi R, Doval DC, et al. Role of circulating tumor cells in determining prognosis in metastatic breast cancer. South Asian J Cancer. 2022;12(01):062–7.
141.
Davis AA, Pierga JY, Dirix LY, et al. The impact of circulating tumor cells (CTCs) detection in metastatic breast cancer (MBC): implications of “indolent” stage IV disease (stage IVindolent). American Society of Clinical Oncology; 2018.
142.
Radovich M, Jiang G, Hancock BA, et al. Association of circulating tumor DNA and circulating tumor cells after neoadjuvant chemotherapy with disease recurrence in patients with triple-negative breast cancer: preplanned secondary analysis of the BRE12-158 randomized clinical trial. JAMA Oncol. 2020;6(9):1410–5.PubMedCrossRef
143.
Olsson E, Winter C, George A, et al. Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. EMBO Mol Med. 2015;7(8):1034–47.PubMedPubMedCentralCrossRef
144.
145.
146.
147.
Browne I. The prognostic and predictive impact of circulating tumour DNA (ctDNA) dynamics in patients with metastatic triple negative breast cancer (TNBC) on olaparib based therapy: results from cohort E of the PlasmaMATCH trial. American Association for Cancer Research; 2023.
148.
Medford AJ, Moy B, Spring LM, Hurvitz SA, Turner NC, Bardia A. Molecular residual disease in breast cancer: detection and therapeutic interception. Clin Cancer Res. 2023;29(22):4540–8.PubMedCrossRef
149.
Chan JCH, Chow JCH, Ho CHM, Tsui TYM, Cho WC. Clinical application of circulating tumor DNA in breast cancer. J Cancer Res Clin Oncol. 2021;147:1431–42.PubMedCrossRef
150.
Janni W, Huober J, Braun T, et al. Multiomic, plasma-only circulating tumor DNA (ctDNA) assay identifies breast cancer patients with minimal residual disease (MRD) and predicts distant recurrence. Cancer Res. 2022;82(12_Supplement):3403.CrossRef
151.
Moding EJ, Nabet BY, Alizadeh AA, Diehn M. Detecting liquid remnants of solid tumors: circulating tumor DNA minimal residual disease. Cancer discovery. 2021;11(12):2968–86.PubMedPubMedCentralCrossRef
152.
Merker JD, Oxnard GR, Compton C, et al. Circulating tumor DNA analysis in patients with cancer: American society of clinical oncology and college of American pathologists Joint review. J Clin Oncol. 2018;36:1631–41.PubMedCrossRef
Metadata
Title
Navigating Breast Cancer Oligometastasis and Oligoprogression: Current Landscape and Future Directions
Authors
Stephanie M. Yoon
Jose G. Bazan
Publication date
23-04-2024
Publisher
Springer US
Published in
Current Oncology Reports
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-024-01529-2
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits